A Study to Test if TEV-53275 is Effective in Relieving Asthma

Inclusion Criteria:

• The participant is an adult female or male ≥18 years of age. Note: Age requirementsare as specified or allowed by local regulations.
• The participant has a diagnosis of asthma for at least 6 months and has been stablewithout exacerbation or change in medications for at least 1 month..
• Current Asthma Therapy: The participant has been maintained for at least 1 month onstable doses of:
• medium or high dose inhaled corticosteroids (ICS)±another controller.
• any fixed dose combination ICS (low, medium, or high) with long-acting betaagonist (LABA)±another controller.
• Women of non-childbearing potential, or congenitally sterile, or 1-yearpostmenopausal. Women of childbearing potential must have a negative β-human chorionicgonadotropin (β-HCG) test result and practice a highly effective method of birthcontrol prior to investigational medicinal product (IMP) administration and 30 weeksafter the dose of IMP.
• The participant, as judged by the investigator, is able to continue their currentasthma maintenance medications throughout the study. NOTE- Additional criteria apply, please contact the investigator for more information.

Exclusion Criteria:

• Life threatening asthma, defined as a history of asthma episode(s) requiringintubation and/or associated hypercapnea, respiratory arrest, hypoxic seizures, orasthma-related syncopal episode(s).
• The participant has a suspected bacterial or viral infection of the upper or lowerrespiratory tract, sinus, or middle ear that has not resolved at least 2 weeks beforethe screening period. Note: Participants who develop an upper respiratoryinfection/lower respiratory infection (URI/LRI) during the run-in period may rescreen 2 weeks after symptoms resolve and undergo coronavirus disease 2019 (COVID-19)testing.
• Participants with a confirmed infection with COVID-19 within 3 months prior to thescreening visit.
• The participant has an eosinophilic condition including hypereosinophilic syndrome,eosinophilic pneumonia, eosinophilic granulomatosis with polyangiitis (EGPA [ChurgStrauss syndrome]), or allergic bronchopulmonary aspergillosis.
• The participant has an active helminthic or parasitic infection currently or withinthe last 6 months.
• The participant has a history of malignancy other than fully resected basal cellcarcinoma of the skin.
• The participant has any clinically significant, uncontrolled medical or psychiatriccondition (treated or untreated) that would interfere with the study schedule orprocedures, interpretation of efficacy results, or compromise the participant'ssafety.
• The participant has known history of, or a positive test result for, hepatitis Bsurface antigen (HBsAg), hepatitis C virus (HCV) antibodies (Ab), or humanimmunodeficiency virus (HIV) Types 1 or 2 Ab (according to 4th generation serologytesting).
• The participant is a pregnant or lactating woman, or plans to become pregnant duringthe study.
• The participant has previously participated in a study with TEV-53275.
• The participant has participated in another study of an IMP (or a medical device)within the previous 30 days or is currently participating in another study of an IMP (or a medical device).
• The participant has been treated with a monoclonal antibody used to treat asthma orother inflammatory conditions within the washout period (5 half-lives), hasdemonstrated hypersensitivity or anaphylaxis to a monoclonal antibody (Appendix G),oris currently using or has used a systemic immunosuppressive medication within the last 6 months. NOTE: Prior depemokimab exposure is prohibited without exception.
• The participant has a history of chronic alcohol or drug abuse within the previous 2years.
• The participant currently smokes or has a smoking history of 10 pack years or more (apack year is defined as smoking 1 pack of cigarettes [20 cigarettes]/day for 1 year),OR the participant used tobacco products within the past year (eg, cigarettes, cigars,chewing tobacco, or pipe tobacco), OR the participant has smoked marijuana within 1month, OR the participant has a history of "vaping" tobacco, marijuana, or any othersubstance within 24 months.
• Vulnerable participants (eg, people kept in detention). NOTE- Additional criteria apply, please contact the investigator for more information